Download PDF
Thorac Cardiovasc Surg 2017; 65(07): 567-571
DOI: 10.1055/s-0036-1583271
Original Thoracic
Georg Thieme Verlag KG Stuttgart · New York

Long-Term Results and Prognostic Factors of Pulmonary Metastasectomy in Patients with Metastatic Transitional Cell Carcinoma

Luca Luzzi
1   Thoracic Surgery Unit, University Hospital of Siena, Siena, Italy
,
Giuseppe Marulli
2   Department of Cardiologic, Thoracic and Vascular Sciences, University of Padua, Padua, Italy
,
Piero Solli
3   Department of Thoracic Surgery, Papworth Hospital NHS Foundation Trust, Cambridge, United Kingdom
,
Giuseppe Cardillo
4   Unit of Thoracic Surgery, Carlo Forlanini Hospital, Rome, Italy
,
Marco Ghisalberti
1   Thoracic Surgery Unit, University Hospital of Siena, Siena, Italy
,
Marco Mammana
2   Department of Cardiologic, Thoracic and Vascular Sciences, University of Padua, Padua, Italy
,
Francesco Carleo
4   Unit of Thoracic Surgery, Carlo Forlanini Hospital, Rome, Italy
,
Lorenzo Spaggiari
5   Department of Thoracic Surgery, European Institute of Oncology, Milan, Italy
,
Federico Rea
2   Department of Cardiologic, Thoracic and Vascular Sciences, University of Padua, Padua, Italy
› Author Affiliations
Further Information

Publication History

11 January 2016

18 March 2016

Publication Date:
05 May 2016 (online)

    Permissions and Reprints All articles of this category

Abstract

Objective We wanted to assess the prognostic factors and the efficacy of the treatment in patients who underwent lung resections for transitional cell carcinoma metastases.

Materials and Methods This is a retrospective, multicenter study. Between January 1995 and May 2014, 69 patients underwent lung metastasectomy with curative intent. We evaluated primary site of the tumor, the role of adjuvant chemotherapy after urological operation, disease-free interval (DFI; lower or higher than 24 months), type of lung resection, number of lung metastases, presence of metastatic lymph nodes, and diameter of the metastasis (less or more than 3 cm).

Results Among 69 patients, 55 (79%) had bladder as primary site of disease and 12 of them received a transurethral bladder resection. Fourteen (21%) patients developed primary tumor in the renal pelvis or ureter; 53 (76%) patients presented with a single metastasis, 16 (24%) with multiple metastasis. The median DFI was 37 months and the median follow-up was 50 months. Sampling lymphadenectomy was done in 42 patients and nodal metastases were found in 7 patients. The overall 5-year survival was 52%, median 62 months. At univariate analysis, the DFI had a significant impact on survival (5-year survival of 58% for patients with DFI ≥ 24 months vs. 46%; p = 0.048) and diameter of metastasis (5-year survival of 59% for diameter less than 3 cm group vs. 33%; p = 0.001). The multivariate analysis confirmed metastasis' diameter as an independent prognostic factor (p = 0.001).

Conclusion Our study found that, in addition to DFI that remains a common prognostic factor in patients with metastatic lung disease, in lung metastases by transitional cell carcinoma, the diameter of the lesion is another significant prognostic factor.

Keywords

metastases/metastasectomy - lung cancer treatment - surgery, medical
 

  • References

  • 1 Lehmann J, Suttmann H, Albers P. , et al. Surgery for metastatic urothelial carcinoma with curative intent: the German experience (AUO AB 30/05). Eur Urol 2009; 55 (06) 1293-1299
    CrossrefPubMedGoogle Scholar
  • 2 Dodd PM, McCaffrey JA, Herr H. , et al. Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma. J Clin Oncol 1999; 17 (08) 2546-2552
    CrossrefPubMedGoogle Scholar
  • 3 von der Maase H, Hansen SW, Roberts JT. , et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000; 18 (17) 3068-3077
    CrossrefPubMedGoogle Scholar
  • 4 Kassouf W, Leibovici D, Munsell MF, Dinney CP, Grossman HB, Kamat AM. Evaluation of the relevance of lymph node density in a contemporary series of patients undergoing radical cystectomy. J Urol 2006; 176 (01) 53-57 , discussion 57
    CrossrefPubMedGoogle Scholar
  • 5 Cowles RS, Johnson DE, McMurtrey MJ. Long-term results following thoracotomy for metastatic bladder cancer. Urology 1982; 20 (04) 390-392
    CrossrefPubMedGoogle Scholar
  • 6 Herr HW, Donat SM, Bajorin DF. Post-chemotherapy surgery in patients with unresectable or regionally metastatic bladder cancer. J Urol 2001; 165 (03) 811-814
    CrossrefPubMedGoogle Scholar
  • 7 Kanzaki R, Higashiyama M, Fujiwara A. , et al. Outcome of surgical resection of pulmonary metastasis from urinary tract transitional cell carcinoma. Interact Cardiovasc Thorac Surg 2010; 11 (01) 60-64
    CrossrefPubMedGoogle Scholar
  • 8 Herr HW. Is metastasectomy for urothelial carcinoma worthwhile?. Eur Urol 2009; 55 (06) 1300-1301
    CrossrefPubMedGoogle Scholar
  • 9 Oosterlinck W, Lobel B, Jakse G, Malmström PU, Stöckle M, Sternberg C. European Association of Urology (EAU) Working Group on Oncological Urology. Guidelines on bladder cancer. Eur Urol 2002; 41 (02) 105-112
    CrossrefPubMedGoogle Scholar
  • 10 Dimopoulos MA, Finn L, Logothetis CJ. Pattern of failure and survival of patients with metastatic urothelial tumors relapsing after cis-platinum-based chemotherapy. J Urol 1994; 151 (03) 598-600 , discussion 600–601
    CrossrefPubMedGoogle Scholar
  • 11 Matsuguma H, Yoshino I, Ito H. , et al; Metastatic Lung Tumor Study Group of Japan. Is there a role for pulmonary metastasectomy with a curative intent in patients with metastatic urinary transitional cell carcinoma?. Ann Thorac Surg 2011; 92 (02) 449-453
    CrossrefPubMedGoogle Scholar